A Phase 2, multicenter, open label, two parts clinical study to evaluate the efficacy and safety of AB-218 in patients with isocitrate dehydrogenase 1 (IDH1) mutant glioma
Clinical Trial Grant
Awarded By
AnHeart Therapeutics, Inc.
Start Date
June 30, 2025
End Date
October 31, 2028
Awarded By
AnHeart Therapeutics, Inc.
Start Date
June 30, 2025
End Date
October 31, 2028